intec pharma ltd  product pipeline review    compare about us  contact us home research category publisher list custom research cart compare research category user guide policies contact us about us site map home  market research report  pharmaceutical  pharmaceutical companies  pharma info market research report intec pharma ltd  product pipeline review   published by global markets direct product code  published february   content info  pages price usd  pdf by email single user license usd  pdf by email site license usd  pdf by email global license intec pharma ltd  product pipeline review   published february   content info  pages description summary global markets directs intec pharma ltd  product pipeline review   provides an overview of the intec pharma ltds pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of intec pharma ltds complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope the report provides brief overview of intec pharma ltd including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of intec pharma ltds human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement latest news and deals relating to the intec pharma ltds pipeline products reasons to buy evaluate intec pharma ltds strategic position with total access to detailed information on its product pipeline assess the growth potential of intec pharma ltd in its therapy areas of focus identify new drug targets and therapeutic classes in the intec pharma ltds rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of intec pharma ltd and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of intec pharma ltd develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of intec pharma ltd and identify potential opportunities in those areas avoid intellectual property rights related issues table of contents product code gmdhccdbtable of contents table of contents list of tables list of figures intec pharma ltd snapshot intec pharma ltd overview key information key facts intec pharma ltd  research and development overview key therapeutic areas intec pharma ltd  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  combination treatment modalities intec pharma ltd  pipeline products glance intec pharma ltd  clinical stage pipeline products phase ii productscombination treatment modalities intec pharma ltd  early stage pipeline products preclinical productscombination treatment modalities intec pharma ltd  drug profiles carbidopa  levodopa product description mechanism of action rd progress zaleplon gr product description mechanism of action rd progress drugs for undisclosed indication product description mechanism of action rd progress intec pharma ltd  pipeline analysis intec pharma ltd  pipeline products by target intec pharma ltd  pipeline products by route of administration intec pharma ltd  pipeline products by molecule type intec pharma ltd  pipeline products by mechanism of action intec pharma ltd  recent pipeline updates intec pharma ltd  dormant projects intec pharma ltd  locations and subsidiaries head office appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tables intec pharma ltd key information intec pharma ltd key facts intec pharma ltd  pipeline by indication  intec pharma ltd  pipeline by stage of development  intec pharma ltd  monotherapy products in pipeline  intec pharma ltd  combination treatment modalities in pipeline  intec pharma ltd  phase ii  intec pharma ltd  preclinical  intec pharma ltd  pipeline by target  intec pharma ltd  pipeline by route of administration  intec pharma ltd  pipeline by molecule type  intec pharma ltd  pipeline products by mechanism of action  intec pharma ltd  recent pipeline updates  intec pharma ltd  dormant developmental projects list of figures intec pharma ltd  pipeline by top  indication  intec pharma ltd  pipeline by stage of development  intec pharma ltd  monotherapy products in pipeline  intec pharma ltd  pipeline by top  target  intec pharma ltd  pipeline products by top  mechanism of action  phone intl  tollfreeus  europe  asia  new for   gii now purchases any market research reports from any publishers for you with noextra cost contact us for more details faq delivery time user license payment options compare multiple reports about contact user guide policies site map  copyright  global information inc all rights reserved biopharmaceuticals market research reports under pharmaceuticals at rnr market research advanced search     salesrnrmarketresearchcom search market research reports market research assistance salesrnrmarketresearchcomon the web refine resultby datelast monthlast  monthslast  monthslast yearlast  years by price  home     life sciences    pharmaceuticals    biopharmaceuticals biopharmaceuticals market research reports globally the biopharmaceuticals market is expected to drive the double digit growth rate the biopharma segment is more costly than traditional medications which needs higher investments and longer development times the biopharmaceuticals segment addreses several therapeutic areas such as neurology infectious diseases cardiovascular oncology etc biopharmaceuticals is categorised into the recombinant proteins insulin erythropoietins interferons colony stimulating factors immunoglobulins recombinant blood factors growth hormones recombinant enzymes interleukins growth factors monoclonal antibodies and purified proteins the recombinant proteins lead the biopharmaceuticals market globally with highest percentage follwed by monoclonal antibodies the recombinant proteins market is considered to be down in developed countries due to biosimilar entry restrictions into the market and increase in cost containment measures the monoclonal antibodies market witness strong gview more globally the biopharmaceuticals market is expected to drive the double digit growth rate the biopharma segment is more costly than traditional medications which needs higher investments and longer development times the biopharmaceuticals segment addreses several therapeutic areas such as neurology infectious diseases cardiovascular oncology etc biopharmaceuticals is categorised into the recombinant proteins insulin erythropoietins interferons colony stimulating factors immunoglobulins recombinant blood factors growth hormones recombinant enzymes interleukins growth factors monoclonal antibodies and purified proteins the recombinant proteins lead the biopharmaceuticals market globally with highest percentage follwed by monoclonal antibodies the recombinant proteins market is considered to be down in developed countries due to biosimilar entry restrictions into the market and increase in cost containment measures the monoclonal antibodies market witness strong growth in developed and emerging economies due to rich late stage pipeline products the global biopharmaceutical market covers top eight regions us germany japan france italy spain uk and canada also the share is increased in emerging markets such as brazil russia india china mexico turkey and south korea the biggest restraint for this market is to get market approval for its products out of every ten drugs only three to four succeed to obtain concerned market approval and ones got the approval turned to be goldmines for investorsthe us is the biggest geographic market witness sharp decline due to spate of policy changes grants and the recent health care reform bill and aarc the industry drives due to its effectiveness and its ability to defend outside the reach of traditional small molecule drugs growth of biopharma in emerging markets approval of new products expansion of therapeutic drugs from existing products increase in biopharmaceutical research activity and participating in merger and acquisition activities including involvement in bioventures the biopharmaceutical market is directing towards licensing deals and allainces to get benefit to enter into the newer technologies of biopharmaceutical segment view less biopharmaceuticals market research reports titlepublishedprice global and chinese biopharmaceuticals industry  market research reportby prof research icals manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industryfirstly the report provides a basic overview of the industry including its definition applications and manufacturing tecjun bio industry markets in chinaby amid er consumption and capital investment for over two decades this new study examines chinas economic trends investment environment industry development supply and demand industry capacity industry structure marketing channels and major industrymay biotechnology products companies in chinaby amid and economy china is one of the worlds major producers for industrial and consumer products far outpacing other economies in the world china is the worlds fastest growing market for the consumptions of goods and services the chinese economy mamay biotechnology products industry industry forecasts  china focusby amid one of the worlds major producers for industrial and consumer products far outpacing other economies in the world china is the worlds fastest growing market for the consumptions of goods and services the chinese economy maintains a high speed grmay emea europe middle east and africa biochar market report by qyresearch group enue million usd market share and growth rate of biochar for these regions from  to  forecast  europe germany france uk russia italy and benelux  middle east saudi arabia israel uae and iran  africa soapr actelion partnering deals and alliances  to by current partnering th insight into the partnering activity of one of the worlds leading life sciences companies on demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and company data the reapr alkermes partnering deals and alliances  to by current partnering th insight into the partnering activity of one of the worlds leading life sciences companies on demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and company data the reapr amylin pharmaceuticals partnering deals and alliances  to by current partnering ides an indepth insight into the partnering activity of one of the worlds leading life sciences companies on demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and company data apr astrazeneca partnering deals and alliances  to by current partnering depth insight into the partnering activity of one of the worlds leading life sciences companies on demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and company data thapr biocon partnering deals and alliances  to by current partnering h insight into the partnering activity of one of the worlds leading life sciences companies on demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and company data the repapr                 next » avail upto  discount on below publisher reports azoth analytics technavio market report intec pharma ltd  product pipeline review   about us • publishers • contact us • cart login  register all industries business  finance  business  financial services  insurance  marketing consumer  food  beverages  consumer goods  food  retailing healthcare  biotechnology  healthcare  medical devices  pharmaceuticals heavy industry  construction  energy  manufacturing  materials  transportation internet  media  ebusiness  internet  media  publishing public sector  defense  education  government telecom  computing  computer technology  fixed networks  software  wireless companycountry reports  company reports  country reports  regional reports   processing intec pharma ltd  product pipeline review   feb    global markets direct   pages  usd  click here to open the popup youve added the following report to your cartclose cart summary total items subtotal      report summary table of contents companies request details related global markets directs intec pharma ltd  product pipeline review   provides an overview of the intec pharma ltds pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of intec pharma ltds complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescopethe report provides brief overview of intec pharma ltd including business description key information and facts and its locations and subsidiariesthe report reviews current pipeline of intec pharma ltds human therapeutic division and enlists all their major and minor projectsthe report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestonesspecial feature on outlicensed and partnered product portfoliothe report summarizes all the dormant and discontinued pipeline projectslatest company statementlatest news and deals relating to the intec pharma ltds pipeline productsreasons to buyevaluate intec pharma ltds strategic position with total access to detailed information on its product pipelineassess the growth potential of intec pharma ltd in its therapy areas of focusidentify new drug targets and therapeutic classes in the intec pharma ltds rd portfolio and develop key strategic initiatives to reinforce pipeline in those areasexploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gapsdevelop strategic initiatives by understanding the focus areas of intec pharma ltd and exploit collaboration and partnership opportunitiesidentify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantageplan mergers and acquisitions effectively by identifying the most promising pipeline of intec pharma ltddevelop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeexplore the dormant and discontinued projects of intec pharma ltd and identify potential opportunities in those areasavoid intellectual property rights related issues table of contentstable of contentslist of tableslist of figuresintec pharma ltd snapshotintec pharma ltd overviewkey informationkey factsintec pharma ltd  research and development overviewkey therapeutic areasintec pharma ltd  pipeline reviewpipeline products by stage of developmentpipeline products  monotherapypipeline products  combination treatment modalitiesintec pharma ltd  pipeline products glanceintec pharma ltd  clinical stage pipeline productsphase ii productscombination treatment modalitiesintec pharma ltd  early stage pipeline productspreclinical productscombination treatment modalitiesintec pharma ltd  drug profilescarbidopa  levodopaproduct descriptionmechanism of actionrd progresszaleplon grproduct descriptionmechanism of actionrd progressdrugs for undisclosed indicationproduct descriptionmechanism of actionrd progressintec pharma ltd  pipeline analysisintec pharma ltd  pipeline products by targetintec pharma ltd  pipeline products by route of administrationintec pharma ltd  pipeline products by molecule typeintec pharma ltd  pipeline products by mechanism of actionintec pharma ltd  recent pipeline updatesintec pharma ltd  dormant projectsintec pharma ltd  locations and subsidiarieshead officeappendixmethodologycoveragesecondary researchprimary researchexpert panel validationcontact usdisclaimerlist of tablesintec pharma ltd key informationintec pharma ltd key factsintec pharma ltd  pipeline by indication intec pharma ltd  pipeline by stage of development intec pharma ltd  monotherapy products in pipeline intec pharma ltd  combination treatment modalities in pipeline intec pharma ltd  phase ii intec pharma ltd  preclinical intec pharma ltd  pipeline by target intec pharma ltd  pipeline by route of administration intec pharma ltd  pipeline by molecule type intec pharma ltd  pipeline products by mechanism of action intec pharma ltd  recent pipeline updates intec pharma ltd  dormant developmental projectslist of figuresintec pharma ltd  pipeline by top  indication intec pharma ltd  pipeline by stage of development intec pharma ltd  monotherapy products in pipeline intec pharma ltd  pipeline by top  target intec pharma ltd  pipeline products by top  mechanism of action  companies mentioned in this reportintec pharma ltd this report does not have a press release associated with it order today format pdf  usd license single user delivery by email   business day the fast market research advantage only the best all of our research is sourced from the most trusted and established global analysts and consultancies client focused from startups to multinationals we focus on providing the right research to our diverse client base shop securely our usbased customer service team and ecommerce systems adhere to the highest data security standards industryleading customer support individualized assistance from our expert staff is never more than an email or phone call away best price guarantee we are committed to providing the best research at the lowest cost we will match any published price for the same report guaranteed easy ordering once you’ve found the right report click ‘order now’ and complete the checkout process using any major credit card check or wirebank transferneed multiuser or enterprise license pricing contact us for a custom quote about the publisher global markets direct is a leading provider of global business intelligence and market analysis it publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industryspecific information publisher details privacy policy  terms of use  flashalerts copyright copy  fast market research inc intec pharma promotes nadav navon phd to chief operating officer intec pharma promotes nadav navon phd to chief operating officer news provided by intec pharma ltd jul    et share this article jerusalem july   prnewswire  intec pharma ltd nasdaq tase ntec a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary accordion pill™ ap platform technology announces the promotion of nadav navon phd executive vice presidentresearch  development and operations to chief operating officer effective immediately dr navon has been instrumental in the growth and development of intec pharma since he joined the team in  he has an outstanding track record in operations having lead the development of the accordion pill through a number of important clinical studies on to our pivotal phase  clinical trial of the accordion pill carbidopalevodopa apcdld for the treatment of advanced parkinsons disease symptoms importantly dr navons intricate knowledge of our ap technology platform and the numerous patents he has filed on behalf of the company will be of great value as we advance our parkinsons program stated jeffrey a meckler intec pharmas chief executive officer as chief operating officer dr navon will continue to play a key role on our senior management team particularly in the oversight of our israeli operations  i look forward to continuing to work with him as we build intec pharma into a world class biopharmaceutical company dr navon has been with intec pharma since march  and has served as the companys executive vice president of research  development and operations since march  before that he served as vice president of research  development and operations prior to joining intec pharma dr navon headed the analytical and quality assurance operations at sharon laboratories ltd a chemical company that develops and manufactures raw materials for the pharmaceutical cosmetic and food industries from  to  prior to that dr navon led a number of research and development projects in the negevs nuclear research center dr navon earned a bachelor of science in chemistry a master of business administration and a phd in inorganic and analytical chemistry each from bengurion university in beersheva israel about intec pharma ltd   intec pharma ltd is a clinicalstage biopharmaceutical company focused on developing drugs based on its proprietary accordion pill platform technology the companys accordion pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism the companys product pipeline includes two product candidates in clinical trial stages accordion pill carbidopalevodopa or apcdld which is being developed for the treatment of parkinsons disease symptoms in advanced parkinsons disease patients and apcbdthc an accordion pill with the two primary cannabinoids contained in cannabis sativa cannabidiol cbd and tetrahydrocannabinol thc which is being developed for various indications including low back neuropathic pain and fibromyalgia cautionary note regarding forwardlooking statements  this press release contains forwardlooking statements about the companys expectations beliefs and intentions forwardlooking statements can be identified by the use of forwardlooking words such as believe expect intend plan may should could might seek target will project forecast continue or anticipate or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters these forwardlooking statements are based on assumptions and assessments made in light of managements experience and perception of historical trends current conditions expected future developments and other factors believed to be appropriate forwardlooking statements in this press release are made as of the date of this press release and the company undertakes no duty to update or revise any such statements whether as a result of new information future events or otherwise forwardlooking statements are not guarantees of future performance and are subject to risks and uncertainties many of which are outside of the companys control important factors that could cause actual results developments and business decisions to differ materially from forwardlooking statements are described in the sections titled risk factors in the companys filings with the securities and exchange commission and include the following the companys ability to develop and commercialize its product candidates and obtain additional financing necessary therefor the length cost and uncertain results of the companys clinical trials including uncertainty regarding the companys ability to enroll the required number of patients therein the potential of adverse side effects other safety risks or legal prohibitions on the use of certain products in certain jurisdictions that could preclude the approval of the companys drug candidates the availability of reimbursement from government authorities and health insurance companies for the companys products the impact of product liability lawsuits and the influence of extensive and costly government regulation contacts jeffrey a meckler chief executive officer intec pharma  jeffreyintecpharmacom   anne marie fields senior vice president lha investor relations  afieldslhaicom source intec pharma ltd jul    et preview intec pharma appoints us life sciences executive and vice chairman jeffrey a meckler as chief executive officer my news release contains wide tables view fullscreen also from this source jul    et intec pharma appoints us life sciences executive and vice mar    et intec pharma provides update on phase iii accordance study of the explore more news releases in similar topics health care  hospitals medical pharmaceuticals pharmaceuticals personnel announcements you just read intec pharma promotes nadav navon phd to chief operating officer news provided by intec pharma ltd jul    et share this article looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search intec pharma ltd  product pipeline review    rnr market research advanced search     salesrnrmarketresearchcom search market research reports ﻿ market research assistance salesrnrmarketresearchcom on the web related markets anesthesia drugsbiosimilarbiopharmaceuticalsclinical trialdietary supplementsdietary supplementdiseases  treatmentcancer drugsdiabetes drugshypertension drugshiv related market reportspharmapoint parkinsons disease  global drug forecast and market analysis to   eventdriven updateintec pharma ltd  product pipeline review  pharmapoint parkinsons disease  global drug forecast and market analysis to  home  life sciences  pharmaceuticals  biopharmaceuticals  report detail intec pharma ltd  product pipeline review   publisher name  global markets direct date feb no of pages  price single user license us  corporate user license us  report descriptiontable of contentnews  blogother reportsour offerings global markets directs intec pharma ltd  product pipeline review   provides an overview of the intec pharma ltds pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of intec pharma ltds complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope the report provides brief overview of intec pharma ltd including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of intec pharma ltds human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement latest news and deals relating to the intec pharma ltds pipeline products reasons to buy evaluate intec pharma ltds strategic position with total access to detailed information on its product pipeline assess the growth potential of intec pharma ltd in its therapy areas of focus identify new drug targets and therapeutic classes in the intec pharma ltds rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of intec pharma ltd and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of intec pharma ltd develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of intec pharma ltd and identify potential opportunities in those areas avoid intellectual property rights related issues intec pharma ltd  product pipeline review   table of contents table of contents  list of tables  list of figures  intec pharma ltd snapshot  intec pharma ltd overview  key information  key facts  intec pharma ltd  research and development overview  key therapeutic areas  intec pharma ltd  pipeline review  pipeline products by stage of development  pipeline products  monotherapy  pipeline products  combination treatment modalities  intec pharma ltd  pipeline products glance  intec pharma ltd  clinical stage pipeline products  phase ii productscombination treatment modalities  intec pharma ltd  early stage pipeline products  preclinical productscombination treatment modalities  intec pharma ltd  drug profiles  carbidopa  levodopa  product description  mechanism of action  rd progress  zaleplon gr  product description  mechanism of action  rd progress  drugs for undisclosed indication  product description  mechanism of action  rd progress  intec pharma ltd  pipeline analysis  intec pharma ltd  pipeline products by target  intec pharma ltd  pipeline products by route of administration  intec pharma ltd  pipeline products by molecule type  intec pharma ltd  pipeline products by mechanism of action  intec pharma ltd  recent pipeline updates  intec pharma ltd  dormant projects  intec pharma ltd  locations and subsidiaries  head office  appendix  methodology  coverage  secondary research  primary research  expert panel validation  contact us  disclaimer  list of tables intec pharma ltd key information  intec pharma ltd key facts  intec pharma ltd  pipeline by indication   intec pharma ltd  pipeline by stage of development   intec pharma ltd  monotherapy products in pipeline   intec pharma ltd  combination treatment modalities in pipeline   intec pharma ltd  phase ii   intec pharma ltd  preclinical   intec pharma ltd  pipeline by target   intec pharma ltd  pipeline by route of administration   intec pharma ltd  pipeline by molecule type   intec pharma ltd  pipeline products by mechanism of action   intec pharma ltd  recent pipeline updates   intec pharma ltd  dormant developmental projects  list of figures intec pharma ltd  pipeline by top  indication   intec pharma ltd  pipeline by stage of development   intec pharma ltd  monotherapy products in pipeline   intec pharma ltd  pipeline by top  target   intec pharma ltd  pipeline products by top  mechanism of action   highspeed data transmission and high volume needs propel fiber optic connectors market fiber optic connectors are a substantial fragment of the global telecommunication industry optical fibers are joined using fiber optic connectors which allow the light conduction between two consecutive optical fibers an additional im…extensive use of digital technologies for diagnostic applications to boost global optical imaging market the global optical imaging system market is predicted to reach us  billion by  it is expected to grow at a stable rate and will post a cagr of more than  in the coming years the growing market infiltration of digital …foremost trends in global pet care market the global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments it is estimated that the global pet care market will grow at a cagr o…china to review its food security laws china has arisen as the globe’s firmest developing economy in addition china brags about the biggest population pool in the world in recent times the one child policy in the republic was terminated this is anticipated to upsur…improving standards of living to boost global consumer durables market consumer durables is a cataloguing of consumer goods that are not essential to be bought very often as they are fashioned in a way so as to last for an extended period of time profits in the consumer durables sector were most profoundly… global and chinese biopharmaceuticals industry  market research report published jun        price us  onwards        pages  the global and chinese biopharmaceuticals industry  market research report is a professional and indepth study on the current state of the global biopharmaceuticals industry with a focus on the chinese market the report provides key statistics on the market status of the biopharmaceuticals manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industryfirstly the report provides a basic overview of the industry including i bio industry markets in china published may        price us  onwards        pages  chinas demand for bio industry has grown at a fast pace in the past decade in the next decade both production and demand will continue to grow the chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output imports  exports consumer consumption and capital investment for over two decades this new study examines chinas economic trends investment environment industry development supply and demand industry capacity industry biotechnology products companies in china published may        price us  onwards        pages  this study focuses on chinas biotechnology products industry assessments and company profiles in the two past decades the industry has been growing at a fast pace the dramatic expansions of the manufacturing capabilities and rising consumer consumptions in china have transformed chinas society and economy china is one of the worlds major producers for industrial and consumer products far outpacing other economies in the world china is the worlds fastest growing market for the consumpti biotechnology products industry industry forecasts  china focus published may        price us  onwards        pages  this study focuses on chinas biotechnology products industry forecasts in the two past decades the industry has been growing at a fast pace the dramatic expansions of the manufacturing capabilities and rising consumer consumptions in china have transformed chinas society and economy china is one of the worlds major producers for industrial and consumer products far outpacing other economies in the world china is the worlds fastest growing market for the consumptions of goods and servic emea europe middle east and africa biochar market report  published apr        price us  onwards        pages  in this report the emea biochar market is valued at usd xx million in  and is expected to reach usd xx million by the end of  growing at a cagr of xx between  and  geographically this report split emea into europe the middle east and africa with sales mt revenue million usd market share and growth rate of biochar for these regions from  to  forecast  europe germany france uk russia italy and benelux  middle east saudi  actelion partnering deals and alliances  to  published apr        price us  onwards        pages  delivery of this report will take  days after purchase this report provides all the information you require to better understand actelion and its partnering interests and activities since  the partnering deals and alliance since  report provides an indepth insight into the partnering activity of one of the worlds leading life sciences companies on demand company reports are prepared upon purchase to ensure inclusion of the most up to  alkermes partnering deals and alliances  to  published apr        price us  onwards        pages  delivery of this report will take  days after purchase this report provides all the information you require to better understand alkermes and its partnering interests and activities since  the partnering deals and alliance since  report provides an indepth insight into the partnering activity of one of the worlds leading life sciences companies on demand company reports are prepared upon purchase to ensure inclusion of the most up to  amylin pharmaceuticals partnering deals and alliances  to  published apr        price us  onwards        pages  delivery of this report will take  days after purchase this report provides all the information you require to better understand amylin pharmaceuticals and its partnering interests and activities since  the partnering deals and alliance since  report provides an indepth insight into the partnering activity of one of the worlds leading life sciences companies on demand company reports are prepared upon purchase to ensure inclusion of t astrazeneca partnering deals and alliances  to  published apr        price us  onwards        pages  delivery of this report will take  days after purchase this report provides all the information you require to better understand astrazeneca and its partnering interests and activities since  the partnering deals and alliance since  report provides an indepth insight into the partnering activity of one of the worlds leading life sciences companies on demand company reports are prepared upon purchase to ensure inclusion of the most up services value for money we believe in optimum utilization of available budget and resources while servicing our clients your market research requirements we keep the same approach in focus to help you get the best value for your s ever growing inventory ranging from the smallest feasible  required data datasheets data facts swot analysis company profiles etc to full research reports that help you make decisions our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than  niche sectors one stop solution need a custom research report on medical devices market require all available business intelligence on d printing industry exploring fb sector of a particular countryregion rnrmarketresearchcom is your onestopsolution to all market intelligence needs we not only offer custom research and consulting services we also bundle reports to meet your needs and help you fetch the data analysis you require for your business dedicated client engagement not limited to only finding relevant reports for you our client engagement team dedicates its efforts to understand your business need and accordingly maps available research data to help you move forward call your client engagement executive any time of your day and get your questions answered in order to make the correct business decision saving time and efforts simply share your research requirement details with us and let us do all the hard work to find required intelligence for you when you add up our one stop solution and dedicated client engagement services mentioned above you obviously know the time and effort saving you do by working with us payment flexibility working with fortune  organizations we understand the importance of being flexible for payments share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done postpurchase research support have questions after reading a report  datasheet bought through us not sure about the methodology used for data available in the research talk to us  share your questions with us and if required we will connect you with the analystsauthors of the reports and ensure you get satisfactory answers for the same need more data  analysis  reports on the topic of your researchproject the rnrmarketresearchcom team is here for you x to support you with your postpurchase requirements subscription offers  packages get in touch with us for more details  salesrnrmarketresearchcom       ad hoc pay  as  you  go  bucket subscriptions fixed cost for of reports customize  personalize as per your needs avail upto  discount on below publisher reports azoth analytics technavio intec pharma granted patent in hong kong for accordion pill carbidopa levodopa employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       intec pharma granted patent in hong kong for accordion pill carbidopa  levodopa tweet   am   life sciences jobs     bullet newest jobs  last  hours   bullet california jobs   bullet massachusetts jobs   bullet new jersey jobs   bullet maryland jobs   bullet washington jobs   view more jobs jerusalem july   prnewswire  intec pharma ltd nasdaq tase ntec a clinicalstage biopharmaceutical company focused on developing drugs based on its proprietary accordion pill platform technology announces that the patent registry intellectual property department of hong kong has issued a certificate of grant of a hong kong patent for an accordion pill containing certain drugs including the combination of carbidopa and levodopa the patent granted under no hk is titled carbidopalevodopa gastroretentive drug delivery and is currently scheduled to remain in force until april  the patent belongs to the companys in patent family which already includes patents granted in the us europe china japan south korea south africa and israelwe remain committed to building out our in patent family in order to fortify our global leadership in gastric retention drug delivery with the accordion pill technology platform and this patent further strengthens that position stated jeffrey a meckler chief executive officer of intec pharma this hong kong patent secures key elements of our accordion pill technology platform and our leading product the accordion pill carbidopalevodopa apcdld in significant markets the apcdld is currently in a global phase iii clinical trial in advanced parkinsons disease and the expanded patent protection will enhance any global commercial efforts for apcdldabout intec pharma ltd intec pharma ltd is a clinicalstage biopharmaceutical company focused on developing drugs based on its proprietary accordion pill platform technology the companys accordion pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism the companys product pipeline includes two product candidates in clinical trial stages accordion pill carbidopalevodopa or apcdld which is being developed for the treatment of parkinsons disease symptoms in advanced parkinsons disease patients and apcbdthc an accordion pill with the two primary cannabinoids contained in cannabis sativa cannabidiol cbd and tetrahydrocannabinol thc which is being developed for various indications including low back neuropathic pain and fibromyalgiacautionary note regarding forwardlooking statementsthis press release contains forwardlooking statements about the companys expectations beliefs and intentions forwardlooking statements can be identified by the use of forwardlooking words such as believe expect intend plan may should could might seek target will project forecast continue or anticipate or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters these forwardlooking statements are based on assumptions and assessments made in light of managements experience and perception of historical trends current conditions expected future developments and other factors believed to be appropriate forwardlooking statements in this press release are made as of the date of this press release and the company undertakes no duty to update or revise any such statements whether as a result of new information future events or otherwise forwardlooking statements are not guarantees of future performance and are subject to risks and uncertainties many of which are outside of the companys control important factors that could cause actual results developments and business decisions to differ materially from forwardlooking statements are described in the sections titled risk factors in the companys filings with the securities and exchange commission and include the following the companys ability to develop and commercialize its product candidates and obtain additional financing necessary therefor the length cost and uncertain results of the companys clinical trials including uncertainty regarding the companys ability to enroll the required number of patients therein the potential of adverse side effects other safety risks or legal prohibitions on the use of certain products in certain jurisdictions that could preclude the approval of the companys drug candidates the availability of reimbursement from government authorities and health insurance companies for the companys products the impact of product liability lawsuits and the influence of extensive and costly government regulationview original contenthttpwwwprnewswirecomnewsreleasesintecpharmagrantedpatentinhongkongforaccordionpillcarbidopalevodopahtmlsource intec pharma ltd read at biospacecom related news intec pharma appoints us life sciences executive and vice chairman jeffrey a meckler as chief executive officer when it comes to abusive drug pricing dont confuse shkreli with hep c drugs intec pharma ceo resigns effecive immediatly interim leader named when the drug you need doesnt make money intec pharma granted us patent for accordion pill comprising levodopa for improved treatment of parkinsons diseases symptoms carts clear one roadblock but face many more intec pharma provides update on phase iii accordance study of the accordion pill carbidopalevodopa in parkinsons disease patients one fda aboutface doesnt mean an orphandrug bonanza intec pharma initiates phase i trial of accordion pill for cannabinoid therapies this new drug could help the us survive a nuclear meltdown please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • intec pharma ltd   • biotechpharma  patent news • clinical  drug product news                 ntec key statistics  intec pharma ltd financial ratios  marketwatch bulletin investor alert expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close intec pharma ltd nasdaq ntec go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus intec pharma ltd market closed  quotes are delayed by  min jul    pm ntec quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite previous close     change   day low day high    week low  week high   company description intec pharma ltd is a clinicalstage biopharmaceutical company which focuses on developing drugs based on its proprietary accordion pill platform technology its product pipeline includes four product candidates in clinical trial stages accordion pill carbidopalevodopa which is being developed  intec pharma ltd is a clinicalstage biopharmaceutical company which focuses on developing drugs based on its proprietary accordion pill platform technology its product pipeline includes four product candidates in clinical trial stages accordion pill carbidopalevodopa which is being developed for the treatment of parkinsons disease symptoms in advanced parkinsons disease patients accordion pill zaleplon which is being developed for the treatment of insomnia including sleep induction and the improvement of sleep maintenance an accordion pill that is being developed for the prevention and treatment of gastroduodenal and small bowel nonsteroidal antiinflammatory drug which induces ulcers and apcbdthc an accordion pill with the two primary cannabinoids contained in cannabis sativa cannabidiol and tetrahydrocannabinol which is being developed for various indications including low back neuropathic pain and fibromyalgia the company was founded by zvi joseph in  and is headquartered in jerusalem israel valuation pe current  price to book ratio  enterprise value to ebitda  efficiency income per employee  liquidity current ratio  quick ratio  cash ratio  profitability return on assets  return on equity  return on total capital  return on invested capital  capital structure officers and executives name age officer since title dr john w kozarich   chairman mr jeffrey a meckler   vice chairman  chief executive officer dr nadav navon   executive vpoperations research  development mr nir sassi   chief financial officer mr giora carni   director  technology director insider actions – purchase – sale  – number of transactions  newslatestcompanyusntec marketwatch news on ntec no news currently available for ntec newsnonmarketwatchcompanyusntec other news on ntec israel cannabis startups are flourishing  pm june    seeking alpha intec expects to hit enrollment target in q in latestage study of accordion pill in parkinsons  am march    seeking alpha fda oks newrons pd med xadago  pm march    seeking alpha biggest movers in manufacturing stocks now – imgn ons spcb bioa  pm jan    investorplacecom intec pharma teams up with micheal j fox foundation to support recruitment for apcdld study  pm nov    seeking alpha  biotechnology stocks to sell now  am nov    investorplacecom intec pharma cuts sample size in latestage study of lead product candidate by almost  shares up   pm nov    seeking alpha  biotechnology stocks to sell now  am oct    investorplacecom biggest movers in manufacturing stocks now – lway lee selb agle  pm oct    investorplacecom biggest movers in manufacturing stocks now – mcur ipci tsro aehr  am oct    investorplacecom biggest movers in manufacturing stocks now – crbp chma crmd nby  am oct    investorplacecom  medical stocks under  to buy now  pm sept    zackscom hottest manufacturing stocks now – eyeg ions hrtx arlz  am aug    investorplacecom biggest movers in manufacturing stocks now – yeco crr gldc ntec  pm june    investorplacecom hottest manufacturing stocks now – cytx ntec cpxx rvp  pm may    investorplacecom intec pharmas latestage study of lead product candidate underway  pm april    seeking alpha hottest manufacturing stocks now – icpt gnca ati vtae  am feb    investorplacecom intec pharma may have a blockbuster  pm sept    barronscom premarket biotech digest gbim soars on celgene deal superbugs d printed drugs  am aug    seeking alpha at a glance intec pharma ltd rmpe building  hartom street har hotzvim jerusalem jm  phone   industry pharmaceuticals sector health carelife sciences fiscal yearend  view sec filings revenue na net income m employees  annual report for ntec newspressreleasecompanyusntec press releases on ntec intec pharma promotes nadav navon phd to chief operating officer  am july    pr newswire  prf intec pharma granted patent in hong kong for accordion pill™ carbidopa  levodopa  am july    pr newswire  prf intec pharma granted patent in hong kong for accordion pill™ carbidopa  levodopa  am july    pr newswire  prf intec pharma appoints us life sciences executive and vice chairman jeffrey a meckler as chief executive officer  am july    pr newswire  prf intec pharma to participate at upcoming june conferences  am may    businesswire  bzx intec pharma granted us patent for accordion pill™ comprising levodopa for improved treatment of parkinsons diseases symptoms  am may    pr newswire  prf intec pharma announces ceo change  am may    pr newswire  prf intec pharma appoints us life sciences executive jeffrey a meckler to its board of directors as vice chairman  am april    pr newswire  prf intec pharma reports  fourth quarter and full year financial results  am april    pr newswire  prf intec pharma provides update on phase iii accordance study of the accordion pill carbidopalevodopa in parkinsons disease patients  am march    pr newswire  prf intec pharma initiates phase i trial of accordion pill for cannabinoid therapies  am march    pr newswire  prf intec pharma to participate in the oppenheimer th annual healthcare conference  pm march    pr newswire  prf intec pharma to participate in the th annual roth conference  am march    businesswire  bzx intec pharma announces  million private placement  am march    pr newswire  prf intec pharma enters into agreement with the michael j fox foundation around its phase iii trial recruitment  am nov    pr newswire  prf intec pharma to sponsor investigator meeting for pivotal phase iii study of accordion pill carbidopalevodopa in advanced parkinsons disease patients  am nov    pr newswire  prf intec pharma announces protocol amendment to phase iii study of accordion pill carbidopalevodopa in advanced parkinsons disease patients  am nov    pr newswire  prf intec pharma granted chinese patent for accordion pilltm carbidopa  levodopa  am oct    businesswire  bzx intec pharma to participate in upcoming september conferences  pm sept    businesswire  bzx intec pharma granted european patent for accordion pill™–carbidopa  levodopa  am sept    businesswire  bzx loading more headlines trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite tlt quoteszigmancomposite jnug x powered by log in  am edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest abreakingelon musk details tesla model  pricing range atesla standard model  will cost  longrange model will cost  pwall street isn’t ready for a point tumble in the dow industrials pbarrons buzz robo  facebook and twitter trading on news pa wild week in washington pthe dark side of cruises pthe highest paid athletes in the world in one chart poj simpson made over  while in prison and won’t have to give any of it to the goldman family p trump to police dont be too nice phere are  coworkers you should avoid like the plague — especially in meetings ptop  most annoying people you may want to unfriend on facebook pthis is one person you should never unfriend on facebook p horrible ways typos could alter the course of your life ppaint your bathroom this color and boost your home’s selling price by  pamericans’ new badge of honor ‘i was blocked by a celebrity’ p weird things i found out about america in my first  hours pbeyond tesla  stocks driving the autonomous car revolution pthese  highly taxed companies need congress to finally act on tax reform pwatch out ‘kids’ are making the most money in this stock market p real ways for millennials to save money not by brownbagging and skipping starbucks loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  intec pharma ltd  product pipeline review   infowiseguyreportscom     chat with us           us         uk login register home report categories premium reports access to  premium reports aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports report categories aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports publisher knowledgestore countries browse by country browse by continent browse by group  region conferences upcoming conferences seminars conferences upcoming conferences seminars countries browse by country browse by continent browse by group  region news  blog press release blog news  blogs press release blogs faqs about us about our company our team life at wgr careers contact us there are no items currently in your basket there are no items currently in your basket search home all reports intec pharma ltd  product pipeline review   intec pharma ltd  product pipeline review   wgr  june  global  pages global markets direct description table of content sample report enquiry before buy related reports intec pharma ltd  product pipeline review  summaryglobal markets direct’s ‘intec pharma ltd  product pipeline review  ’ provides an overview of the intec pharma ltd’s pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of intec pharma ltd’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescope the report provides brief overview of intec pharma ltd including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of intec pharma ltd’s human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement  latest news and deals relating to the intec pharma ltd’s pipeline productsreasons to buy evaluate intec pharma ltd’s strategic position with total access to detailed information on its product pipeline assess the growth potential of intec pharma ltd in its therapy areas of focus identify new drug targets and therapeutic classes in the intec pharma ltd’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of intec pharma ltd and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of intec pharma ltd develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of intec pharma ltd and identify potential opportunities in those areas avoid intellectual property rights related issues table of contentstable of contents list of tables list of figures intec pharma ltd snapshot intec pharma ltd overview key information key facts intec pharma ltd  research and development overview key therapeutic areas intec pharma ltd  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  combination treatment modalities intec pharma ltd  pipeline products glance intec pharma ltd  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities intec pharma ltd  early stage pipeline products preclinical productscombination treatment modalities intec pharma ltd  drug profiles carbidopa  levodopa product description mechanism of action rd progress zaleplon gr product description mechanism of action rd progress baclofen gr product description mechanism of action rd progress several undisclosed projects product description mechanism of action rd progress intec pharma ltd  pipeline analysis intec pharma ltd  pipeline products by target intec pharma ltd  pipeline products by route of administration intec pharma ltd  pipeline products by molecule type intec pharma ltd  pipeline products by mechanism of action intec pharma ltd  recent pipeline updates intec pharma ltd  locations and subsidiaries head office appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesintec pharma ltd key information intec pharma ltd key facts intec pharma ltd  pipeline by indication  intec pharma ltd  pipeline by stage of development  intec pharma ltd  monotherapy products in pipeline  intec pharma ltd  combination treatment modalities in pipeline  intec pharma ltd  phase ii  intec pharma ltd  phase i  intec pharma ltd  preclinical  intec pharma ltd  pipeline by target  intec pharma ltd  pipeline by route of administration  intec pharma ltd  pipeline by molecule type  intec pharma ltd  pipeline products by mechanism of action  intec pharma ltd  recent pipeline updates  list of figuresintec pharma ltd  pipeline by top  indication  intec pharma ltd  pipeline by stage of development  intec pharma ltd  monotherapy products in pipeline  intec pharma ltd  pipeline by top  target  intec pharma ltd  pipeline by top  route of administration  intec pharma ltd  pipeline by top  molecule type  intec pharma ltd  pipeline products by top  mechanism of action   request a sample report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro do you have any specific field of interest confirm make an enquiry before buying this report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro your enquiry confirm purchase this market research report usd gbp euro yen inr user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  add to cart buy now   email report   sample report   save page   any questions   download information   check discount   download order form   email report   sample report   save page   any questions   download information   check discount   download order form contact us akash anand domain head business development saleswiseguyreportscom     us     uk rishabh arora domain head business development saleswiseguyreportscom  abu koshy domain head business development saleswiseguyreportscom     related reports × tell a friend about this report your name your email friends name friends email your enquiry send  fiercepharma skip to main content twitter linkedin search  any homepagepharmamaregulatoryfinancialscorporatelegalmanufacturingmaoutsourcingregulatorysupply chaindrug safetypartneringmarketingregulatorydtc advertisingdigital and social mediadata and analyticslaunchespharma asiamamanufacturingrdregulatorysales and marketingfinancialsanimal healthmardregulatoryveterinarianfinancialsvaccinesdrug deliveryrdregulatorypartneringvaccinesdealsinfectious diseasesrdregulatory sort by published date order oldestnewest eventfiercebiotech nd drug development forumseptember    boston ma  sponsored by fiercebiotech join  csuite biotech executives at the unmatched educational venue for drug development professionals this event will cover the greatest partnership challenges that biotech companies face throughout the entire product and corporate development cycle to learn more or register click here more info popular content astrazenecas mystic shortfall is an immunooncology shakeup for bristolmyers and a bolster for merck and roche jul   new glaxosmithkline chief walmsley makes early mark with sweeping pharma overhaul jul   astrazeneca merck team up on lynparza combos in collaboration worth up to b jul   roche’s deep discount for ms drug ocrevus pays off big for swiss drugmaker jul   lillys baricitinib setback gives pfizers xeljanz a clear shot at newer rivals jul    fiercepharma skip to main content twitter linkedin search  any ebookebriefeventexecutive summaryjobmultimediapaid marketplaceresearchsurveyvideowebinarwhitepaper  any homepagepharmamaregulatoryfinancialscorporatelegalmanufacturingmaoutsourcingregulatorysupply chaindrug safetypartneringmarketingregulatorydtc advertisingdigital and social mediadata and analyticslaunchespharma asiamamanufacturingrdregulatorysales and marketingfinancialsanimal healthmardregulatoryveterinarianfinancialsvaccinesdrug deliveryrdregulatorypartneringvaccinesdealsinfectious diseasesrdregulatory sort by published date order oldestnewest webinarexploring adc pharmacokinetics using qsp modeling strategiesseptember    pm et  am pt  presented by applied biomath the pharmacokinetics pk of adc therapeutics typically show a discrepancy between the pk of total antibody and that of conjugated antibody carrying one or more payload molecules this will present how quantitative systems pharmacology modeling approaches provide biological insights into the impact of drugtoantibody ratio and the resulting changes in molecular properties on overall pk and relative payload disposition as observed in preclinical and clinical studies register now more info webinar small size big plans – product development advice for small companiesaugust    pm etam pt  presented by rho this webinar will provide advice on how to set your small company up for longterm success through the use of strategic development plans purposeful outsourcing patent protection partnership strategies and provide specific examples of success stories and lessons learned register now more info webinarmagnify patient engagement productivity with unified cognitive search on salesforceaugust    pm et  am pt  presented by persistent systems obtain greater productivity and effectiveness in the matters of patient and member engagement this webinar will present the packaged solution that enables single window proactive access within the salesforce service console for customer service representatives  supervisors to effectively manage their patient and member populations register now more info webinaraccelerate clinical trials with rapid application developmentaugust     pm et   am pt  presented by salesforce clinical trials are at a crossroads biopharmaceutical companies must accelerate the development and approval of tailored therapeutics but legacy clinical it infrastructure makes it difficult to keep up this webinar will highlight how life science companies are building connected rd applications using an agile intelligent platform that connects key stakeholders including sponsors cros sites and subjects learn from customer success stories and live demonstrations and see how you can apply this approach to turbocharge your own clinical programs register now more info webinarbring your life sciences content management strategy into the digital ageaugust    pm et  am pt  presented by medidata solutions the life sciences industry is undergoing a digital transformation as legacy it systems move into the cloud and cohesive transition strategies are required whether you’re in quality control clinical operations it regulatory compliance or manage another area of the trial join medidata and box explore how to build a total regulated and nonregulated content management strategy to match todays unique challenges including implementing technology via a single userfriendly platform register now more info webinarimplementing a common data model in a realworld analytics environmentsponsored by evidera this webinar “implementing a common data model cdm in a realworld informatics and analytics environment headwinds or smooth sailing” explores cdm research vs practice and the issues encountered when implementing a cdm in practice including alternative approaches and potential best practices watch now more info whitepaperrealworld evidence in payer negotiations – what’s in your playbooksponsored by evidera realworld evidence plays an important role in acquiring and defending optimal payer position read our white paper on the use of rwe to align with payers on environment  value vs competitors at launch defend payer positioning and potentially bolster and extend the value of onmarket products more info webinarhow modern quality systems are transforming change managementnow ondemand  presented by veeva assessing impact and creating and executing a change plan are difficult with global stakeholders and multitude of systems during this webinar learn frameworks and best practices for transforming change management register now more info webinarconnecting the drug development journey with datadriven insightsjuly    am et  am pt  presented by parexel while biopharmaceutical companies face challenges in generating and integrating meaningful insights that drive timely and actionable decisions aggregating and leveraging the right data to drive value requires a broad range of services working together to generate insights across the entire drug development spectrum hear parexel experts derive datadriven insights and how these insights can benefit many essential drug development areas register now more info webinaraccelerate your speed to market new options for generic drug packaging  deliverynow available ondemand  presented by west pharmaceutical services quality speed simplicity learn how a new elastomeric closure formulation turnkey extractables and leachables package and a flexible supply can help generics manufacturers make the move to market join this webinar with west experts and learn about generics market trends and acceltra™ brand program attributes that address generic injectable drug manufacturer issues and ensure a fast move to market register now more info popular content astrazenecas mystic shortfall is an immunooncology shakeup for bristolmyers and a bolster for merck and roche jul   new glaxosmithkline chief walmsley makes early mark with sweeping pharma overhaul jul   astrazeneca merck team up on lynparza combos in collaboration worth up to b jul   roche’s deep discount for ms drug ocrevus pays off big for swiss drugmaker jul   lillys baricitinib setback gives pfizers xeljanz a clear shot at newer rivals jul   microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft home  intecpharma the accordion pill™ a drug delivery solution for key unmet needsread more about us intec pharma is a drug development company applying its innovative proprietary gastric retention technology to develop improved formulations of drugs read more technology the accordion pill™ a novel gastroretentive delivery system significantly improves the pharmacokinetics of drugs with either narrow absorption window or poorly soluble drugs that belong to biopharmaceutics classification system bcs class ii and class iv the accordion pill™ is designed for drugs that are characterized by one of the following • narrow absorption window poor colonic absorption • poor solubility bcs class ii or iv • act locally in the stomach or in the upper part of the gi tract • adverse effects correlate with the drug reaching the distal parts of the gi tract watch video read more events  intecpharma sitemap terms of use home about management board of directors scientific advisory team technology narrow absorption window drugs poorly soluble drugs pipeline ap – cdld ap – zp partnering investors company filings press releases sec filings stock quote corporate governance events events contact us investors  intecpharma home  investors investors intec pharma ltd is a latestage biopharmaceutical company focused on developing drugs based on its proprietary accordion pill platform technology the company’s accordion pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism the company’s product pipeline currently includes product candidates in various clinical trial stages accordion pill carbidopalevodopa or apcdld is being evaluated in a us phase iii clinical trial as a treatment for parkinson’s disease symptoms in advanced parkinson’s disease patients accordion pill zaleplon or apzp is being developed as a treatment for insomnia including sleep induction and the improvement of sleep maintenance an accordion pill is being developed for the prevention and treatment of gastroduodenal and small bowel nonsteroidal antiinflammatory drug induced ulcers and an accordion pill for cannabinoid therapies or apcbdthc is expected to initiate clinical trials for a pain indication in the first quarter of  for share performance and additional information published in the tase use the following link investor relations afieldslhaicom investors company filings press releases sec filings stock quote corporate governance press releases   pm intec pharma appoints us life sciences executive and vice chairman jeffrey a meckler as chief executive officer   am intec pharma appoints us life sciences executive jeffrey a meckler to its board of directors as vice chairman   am intec pharma initiates phase i trial of accordion pill for cannabinoid therapies  intecpharma sitemap terms of use home about management board of directors scientific advisory team technology narrow absorption window drugs poorly soluble drugs pipeline ap – cdld ap – zp partnering investors company filings press releases sec filings stock quote corporate governance events events contact us intec pharma ltd  product pipeline review       gmt office hours  uscan toll free  us office no home categories become publisher news about us contact us select category consumer goods food  beverage heavy industry life sciences marketing  market research public sector service industries technology  media semiconductor chemical and materials metallurgical market research search home  life sciences  pharmaceuticals  general pharmaceuticals intec pharma ltd  product pipeline review   published feb  format pdf  global markets direct  number of pages   code mrs   report details table of content inquiry for buying request sample   global markets directs intec pharma ltd product pipeline review  provides an overview of the intec pharma ltds pharmaceutical research and development focus   this report provides comprehensive information on the current therapeutic developmental pipeline of intec pharma ltds complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects   global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis   the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products   scope   the report provides brief overview of intec pharma ltd including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of intec pharma ltds human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones  special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement  latest news and deals relating to the intec pharma ltds pipeline products   reasons to buy   evaluate intec pharma ltds strategic position with total access to detailed information on its product pipeline assess the growth potential of intec pharma ltd in its therapy areas of focus identify new drug targets and therapeutic classes in the intec pharma ltds rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of intec pharma ltd and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of intec pharma ltd develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of intec pharma ltd and identify potential opportunities in those areas avoid intellectual property rights related issues table of contents table of contents  list of tables  list of figures  intec pharma ltd snapshot  intec pharma ltd overview  key information  key facts  intec pharma ltd  research and development overview  key therapeutic areas  intec pharma ltd  pipeline review  pipeline products by stage of development  pipeline products  monotherapy  pipeline products  combination treatment modalities  intec pharma ltd  pipeline products glance  intec pharma ltd  clinical stage pipeline products  phase ii productscombination treatment modalities  intec pharma ltd  early stage pipeline products  preclinical productscombination treatment modalities  intec pharma ltd  drug profiles  carbidopa  levodopa  product description  mechanism of action  rd progress  zaleplon gr  product description  mechanism of action  rd progress  drugs for undisclosed indication  product description  mechanism of action  rd progress  intec pharma ltd  pipeline analysis  intec pharma ltd  pipeline products by target  intec pharma ltd  pipeline products by route of administration  intec pharma ltd  pipeline products by molecule type  intec pharma ltd  pipeline products by mechanism of action  intec pharma ltd  recent pipeline updates  intec pharma ltd  dormant projects  intec pharma ltd  locations and subsidiaries  head office    appendix  methodology  coverage  secondary research  primary research  expert panel validation  contact us  disclaimer    list of tables   intec pharma ltd key information  intec pharma ltd key facts  intec pharma ltd  pipeline by indication   intec pharma ltd  pipeline by stage of development   intec pharma ltd  monotherapy products in pipeline   intec pharma ltd  combination treatment modalities in pipeline   intec pharma ltd  phase ii   intec pharma ltd  preclinical   intec pharma ltd  pipeline by target   intec pharma ltd  pipeline by route of administration   intec pharma ltd  pipeline by molecule type   intec pharma ltd  pipeline products by mechanism of action   intec pharma ltd  recent pipeline updates   intec pharma ltd  dormant developmental projects    list of figures   intec pharma ltd  pipeline by top  indication   intec pharma ltd  pipeline by stage of development   intec pharma ltd  monotherapy products in pipeline   intec pharma ltd  pipeline by top  target   intec pharma ltd  pipeline products by top  mechanism of action   inquiry for buying please fill your details below to inquire about this report  indicates required fields name email phone name of company titledesignation country name select country andorra united arab emirates afghanistan antigua and barbuda anguilla albania armenia angola antarctica argentina american samoa austria australia aruba åland islands azerbaijan bosnia and herzegovina barbados bangladesh belgium burkina faso bulgaria bahrain burundi benin saint barthélemy bermuda brunei darussalam bolivia plurinational state of bonaire sint eustatius and saba brazil bahamas bhutan bouvet island botswana belarus belize canada cocos keeling islands congo the democratic republic of the central african republic congo switzerland côte divoire cook islands chile cameroon china colombia costa rica cuba cape verde curaçao christmas island cyprus czech republic germany djibouti denmark dominica dominican republic algeria ecuador estonia egypt western sahara eritrea spain ethiopia finland fiji falkland islands malvinas micronesia federated states of faroe islands france gabon united kingdom grenada georgia french guiana guernsey ghana gibraltar greenland gambia guinea guadeloupe equatorial guinea greece south georgia and the south sandwich islands guatemala guam guineabissau guyana hong kong heard island and mcdonald islands honduras croatia haiti hungary indonesia ireland israel isle of man india british indian ocean territory iraq iran islamic republic of iceland italy jersey jamaica jordan japan kenya kyrgyzstan cambodia kiribati comoros saint kitts and nevis korea democratic peoples republic of korea republic of kuwait cayman islands kazakhstan lao peoples democratic republic lebanon saint lucia liechtenstein sri lanka liberia lesotho lithuania luxembourg latvia libya morocco monaco moldova republic of montenegro saint martin french part madagascar marshall islands macedonia the former yugoslav republic of mali myanmar mongolia macao northern mariana islands martinique mauritania montserrat malta mauritius maldives malawi mexico malaysia mozambique namibia new caledonia niger norfolk island nigeria nicaragua netherlands norway nepal nauru niue new zealand oman panama peru french polynesia papua new guinea philippines pakistan poland saint pierre and miquelon pitcairn puerto rico palestinian state of portugal palau paraguay qatar réunion romania serbia russian federation rwanda saudi arabia solomon islands seychelles sudan sweden singapore saint helena ascension and tristan da cunha slovenia svalbard and jan mayen slovakia sierra leone san marino senegal somalia suriname south sudan sao tome and principe el salvador sint maarten dutch part syrian arab republic swaziland turks and caicos islands chad french southern territories togo thailand tajikistan tokelau timorleste turkmenistan tunisia tonga turkey trinidad and tobago tuvalu taiwan province of china tanzania united republic of ukraine uganda united states minor outlying islands united states uruguay uzbekistan holy see vatican city state saint vincent and the grenadines venezuela bolivarian republic of virgin islands british virgin islands us viet nam vanuatu wallis and futuna samoa yemen mayotte south africa zambia zimbabwe how can we help you refresh captcha submit request sample please fill your details below to receive sample report  indicates required fields name email phone name of company titledesignation country name select country andorra united arab emirates afghanistan antigua and barbuda anguilla albania armenia angola antarctica argentina american samoa austria australia aruba åland islands azerbaijan bosnia and herzegovina barbados bangladesh belgium burkina faso bulgaria bahrain burundi benin saint barthélemy bermuda brunei darussalam bolivia plurinational state of bonaire sint eustatius and saba brazil bahamas bhutan bouvet island botswana belarus belize canada cocos keeling islands congo the democratic republic of the central african republic congo switzerland côte divoire cook islands chile cameroon china colombia costa rica cuba cape verde curaçao christmas island cyprus czech republic germany djibouti denmark dominica dominican republic algeria ecuador estonia egypt western sahara eritrea spain ethiopia finland fiji falkland islands malvinas micronesia federated states of faroe islands france gabon united kingdom grenada georgia french guiana guernsey ghana gibraltar greenland gambia guinea guadeloupe equatorial guinea greece south georgia and the south sandwich islands guatemala guam guineabissau guyana hong kong heard island and mcdonald islands honduras croatia haiti hungary indonesia ireland israel isle of man india british indian ocean territory iraq iran islamic republic of iceland italy jersey jamaica jordan japan kenya kyrgyzstan cambodia kiribati comoros saint kitts and nevis korea democratic peoples republic of korea republic of kuwait cayman islands kazakhstan lao peoples democratic republic lebanon saint lucia liechtenstein sri lanka liberia lesotho lithuania luxembourg latvia libya morocco monaco moldova republic of montenegro saint martin french part madagascar marshall islands macedonia the former yugoslav republic of mali myanmar mongolia macao northern mariana islands martinique mauritania montserrat malta mauritius maldives malawi mexico malaysia mozambique namibia new caledonia niger norfolk island nigeria nicaragua netherlands norway nepal nauru niue new zealand oman panama peru french polynesia papua new guinea philippines pakistan poland saint pierre and miquelon pitcairn puerto rico palestinian state of portugal palau paraguay qatar réunion romania serbia russian federation rwanda saudi arabia solomon islands seychelles sudan sweden singapore saint helena ascension and tristan da cunha slovenia svalbard and jan mayen slovakia sierra leone san marino senegal somalia suriname south sudan sao tome and principe el salvador sint maarten dutch part syrian arab republic swaziland turks and caicos islands chad french southern territories togo thailand tajikistan tokelau timorleste turkmenistan tunisia tonga turkey trinidad and tobago tuvalu taiwan province of china tanzania united republic of ukraine uganda united states minor outlying islands united states uruguay uzbekistan holy see vatican city state saint vincent and the grenadines venezuela bolivarian republic of virgin islands british virgin islands us viet nam vanuatu wallis and futuna samoa yemen mayotte south africa zambia zimbabwe how can we help you refresh captcha submit related reports global sialic acid market professional survey report  jul  qy research  pages    code  mrs   this report studies sialic acid in global market especially in north america china europe southeast asia japan and india with production revenue consumption import and export in these regions from  to  and forecast to  this report focuses on top manufacturers in global market with production price revenue and market share for each manufacturer covering  nzp  nacalai usa  rs pharmchem  yhc  jk biotech read more global sodium hyaluronate market professional survey report  jul  qy research  pages    code  mrs   this report studies sodium hyaluronate in global market especially in north america china europe southeast asia japan and india with production revenue consumption import and export in these regions from  to  and forecast to  this report focuses on top manufacturers in global market with production price revenue and market share for each manufacturer covering  contipro  lifecore biomedical  seikagaku corporation  vsy b read more global ultrasound gel warmer market professional survey report  jul  qy research  pages    code  mrs   this report studies ultrasound gel warmer in global market especially in north america china europe southeast asia japan and india with production revenue consumption import and export in these regions from  to  and forecast to  this report focuses on top manufacturers in global market with production price revenue and market share for each manufacturer covering  parker laboratories  vermed  athena medical products  ke read more global and europe bcg vaccine market  analysis and outlook to  jul  eu research  pages    code  mrs   this report presents a comprehensive overview of the bcg vaccine market in europe this shares the history data information from  to  and forecast from  to  this report provides a detailed analysis of the market its dynamics structure characteristics main players growth and demand drivers etc as a detailed analysis report it covers all details inside analysis and opinion in bcg vaccine industry this report focus global and europe market it covers details playe read more global onychomycosis tinea unguium drug detailed analysis report  jul  detailed analysis research  pages    code  mrs   this report splits onychomycosis tinea unguium drug by product drug form by product usage type this shares the history data information from  to  and forecast from  to  and this report mainly introduces volume and value market share by players by regions by product type by consumers and also their price change details as a detailed analysis report it covers all details inside analysis and opinion in onychomycosis tinea unguium drug industry this report fo read more life science analytics  global market outlook  jun  stratistics mrc  pages    code  mrs   according to stratistics mrc the global life science analytics market is expected to grow from  billion in  to reach  billion by  with a cagr of  some of the factors propelling the market growth are raising demand for analytics in sales and marketing applications increasing need of these solutions especially in clinical trials and improvements in technological advancements however lack of skilled professionals huge implementation costs and financial limitations read more chronic kidney disease ckd drugs  global market outlook  jul  stratistics mrc  pages    code  mrs   according to stratistics mrc the global chronic kidney disease ckd drugs market is expected to grow from  billion in  to reach  billion by  with a cagr of  drivers that are shaping the global market include growing incidences of chronic kidney diseases rise in aged population rising incidence of diabetes and obesity related disorders significant unmet requirements and beneficial reimbursement policies on the other hand factors such as intense competition fr read more acaricides  global market outlook  jul  stratistics mrc  pages    code  mrs   according to stratistics mrc the global acaricides market is expected to grow from  million in  to reach  million by  with a cagr of  high demand for meat dairy products and crops growth in crop protection industry and rise in productivity are some of the factors propelling the market growth however increase in cost alternative acaricides sources and regulatory restrictions are the factors suppressing the market on the other hand expansion of bioactive aca read more global and united states bacillus subtilis depth research report  jul  united states research  pages    code  mrs   this report mainly introduces volume and value market share by players by regions by product type by consumers and also their price change details as a depth research report it covers all details inside analysis and opinion in bacillus subtilis industry this report focus united states market it covers details players regions product type and other details as following major companies bayer germany basf germany tonglu huifeng china kernel biotech china w read more global bacterial vaginosis drug market rport  jun  bisreport  pages    code  mrs   global bacterial vaginosis drug market report  full report  multi license section  section price as below page  chart and figure  publisher bisreport delivery time  hour contact salesbisreportcom phone  with the slowdown in world economic growth the bacterial vaginosis drug industry has also suffered a certain impact but still maintained a relatively optimistic growth the past four years bacterial vaginosis drug market size to maintain read more payment mode single user  usd multi user  usd corporate user  usd latest report  global nonslip epoxy glass flake paint market research report  global parking sensors market research report  global nitrogen oxide sensor market research report  global nuclear density gauge market research report  global automotive interior materials market research report view more latest news global chitosan market set for rapid growth to reach usd  billion by  zion market research has published a new report titled chitosan market for water treatment biomed development of ecommerce to reshape global mobile hotspot router market mobile hotspot is a popular feature on smart phones that provide wireless internet access on many global carotenoids market is expected to reach around usd  billion in  zion market research has published a new report titled carotenoids market by type astaxanthin be soaring demand from food  beverages industry to act as prime driving for ascorbic acid market reports zion market research ascorbic acid is extensively available in nature mostly rich in leafy vegetables and fresh fruits global energy management system ems market is set for a rapid growth and is expected to reach usd  million by  zion market research has published a new report titled energy management system market ems by so view more single user  usd view pricing find help how to order disclaimer faqs return policy sitemap our company about us terms and conditions privacy policy we accept the following payment methods     market research store  market research reports